Cited by 19Autoimmune and Inflammatory DisordersHidradenitis Suppurativa and TreatmentsInflammasome and immune disorders

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review

Open access

Yamanaka, Keiichi·2024·The Journal of Dermatology

DOI 10.1111/1346-8138.17031PMC PMC11483966

Open this paper in CoChat — free account

Abstract

Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are stubborn inflammatory skin diseases categorized as neutrophilic hypodermal dermatoses. These conditions exhibit connections with other autoinflammatory disorders driven by immune responses. Their pathogenesis is complex, rooted in significant imbalances in both innate and adaptive immune systems, particularly featuring elevated levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-8, IL-17, and IL-23. Studies involving skin tissue pathology and serology have indicated that targeting specific cytokines can bring therapeutic benefits. Indeed, many patients in clinical settings have responded positively to such interventions. Yet, given the diverse cytokines in play, focusing on a single one with antibody therapy might not always be effective. When resistance to biologics emerges, a combined approach targeting multiple overactive cytokines with immunosuppressants, for example cyclosporine and Janus kinase inhibitors, could be an option. In the current review, we explore recent therapeutic developments for PG and HS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/1346-8138.17031

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F. A., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 813
Hidradenitis suppurativa: A comprehensive review
Alikhan, A., Lynch, P., & Eisen, D. B. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.911 · Cited by 708
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
Brooklyn, T., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S. (2005) · Gut · doi:10.1136/gut.2005.074815 · Cited by 647
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 473
Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines
Henry, C. M., Sullivan, G. P., Clancy, D. M., Afonina, I. S., Kulms, D., & Martin, S. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.072 · Cited by 330
Pyoderma gangrenosum
Maverakis, E., Marzano, A. V., Le, S. T., Callen, J. P., Brüggen, M., Guenova, E., Dissemond, J., Shinkai, K., & Langan, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0213-x · Cited by 322
Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
Kelly, G. A., Hughes, R., McGarry, T., Born, M., Adamzik, K., Fitzgerald, R., Lawlor, C., Tobin, A., Sweeney, C. M., & Kirby, B. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14075 · Cited by 312
Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands
Yu, C. C. W., & Cook, M. G. (1990) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1990.tb06264.x · Cited by 304
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa
Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., Dinarello, C. A., van der Meer, J. W. M., Rigopoulos, D., & Giamarellos‐Bourboulis, E. J. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3903 · Cited by 268
Incidence, Mortality, and Disease Associations of Pyoderma Gangrenosum in the United Kingdom: A Retrospective Cohort Study
Langan, S., Groves, R. W., Card, T. R., & Gulliford, M. C. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.130 · Cited by 265
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments
Maronese, C. A., Pimentel, M. A., Li, M. M., Genovese, G., Ortega‐Loayza, A. G., & Marzano, A. V. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00699-8 · Cited by 251
Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome
Marzano, A. V., Fanoni, D., Antiga, E., Quaglino, P., Caproni, M., CROSTI, C., Meroni, P. L., & Cugno, M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12394 · Cited by 241
Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy
Moran, B., Sweeney, C. M., Hughes, R., Malara, A., Kirthi, S., Tobin, A., Kirby, B., & Fletcher, J. M. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.033 · Cited by 226
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview
Toussirot, É., & Aubin, F. (2016) · RMD Open · doi:10.1136/rmdopen-2015-000239 · Cited by 213
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
Blok, J. L., Li, K., Brodmerkel, C. M., Horvatovich, P. L., Jonkman, M. F., & Horváth, B. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14338 · Cited by 194
Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases
Marzano, A. V., Cugno, M., Trevisan, V., Fanoni, D., Venegoni, L., Berti, E., & CROSTI, C. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04201.x · Cited by 191
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
de Medeiros, A. K. A., Speeckaert, R., Desmet, E., Gele, M. V., Schepper, S. D., & Lambert, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164080 · Cited by 186
Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?
Matusiak, Ł., Bieniek, A., & Szepietowski, J. C. (2009) · Acta Dermato Venereologica · doi:10.2340/00015555-0749 · Cited by 172
A Comprehensive Review of Neutrophilic Diseases
Marzano, A. V., Borghi, A., Wallach, D., & Cugno, M. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8621-8 · Cited by 161
Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy
Lowe, M. M., Naik, H. B., Clancy, S., Pauli, M. L., Smith, K. M., Bi, Y., Dunstan, R. W., Gudjonsson, J. E., Paul, M., Harris, H. W., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139932 · Cited by 158
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial
Vossen, A. R. J. V., van Doorn, M. B. A., van der Zee, H. H., & Prens, E. P. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.046 · Cited by 135
Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases
Marzano, A. V., Ortega‐Loayza, A. G., Heath, M. S., Morse, D., Genovese, G., & Cugno, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01059 · Cited by 126
A Comparison of International Management Guidelines for Hidradenitis Suppurativa
Hendricks, A. J., Hsiao, J. L., Lowes, M. A., & Shi, V. Y. (2019) · Dermatology · doi:10.1159/000503605 · Cited by 121
An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
Leslie, K. S., Tripathi, S. V., Nguyen, T. V., Pauli, M. L., & Rosenblum, M. D. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.09.044 · Cited by 119
Canakinumab in adults with steroid‐refractory pyoderma gangrenosum
Kolios, A. G. A., Maul, J., Meier-Schiesser, B., Kerl, K., Traidl‐Hoffmann, C., Hertl, M., Zillikens, D., Röcken, M., Ring, J., Facchiano, A., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14037 · Cited by 116
Hidradenitis suppurativa: the role of immune dysregulation
Kelly, G., Sweeney, C. M., Tobin, A., & Kirby, B. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12550 · Cited by 113
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies*
Alavi, A., Hamzavi, I. H., Brown, K., Santos, L. L., Zhu, Z., Liu, H., Howell, M. D., & Kirby, J. S. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20969 · Cited by 95
The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier
Macleod, T., Berekméri, A., Bridgewood, C., Stacey, M. A., McGonagle, D., & Wittmann, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808012 · Cited by 91
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial
Casseres, R. G., Prussick, L., Zancanaro, P. Q., Rothstein, B. E., Joshipura, D., Saraiya, A. R., Turkowski, Y., Au, S. C., Alomran, A. M., Abdat, R., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.005 · Cited by 87
The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum
Caproni, M., Antiga, E., Volpi, W., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13670 · Cited by 83
Classic Ulcerative Pyoderma Gangrenosum Is a T Cell-Mediated Disease Targeting Follicular Adnexal Structures: A Hypothesis Based on Molecular and Clinicopathologic Studies
Wang, E. A., Steel, A., Luxardi, G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01980 · Cited by 70
TNF-α inhibitors in the treatment of hidradenitis suppurativa
Savage, K. T., Flood, K. S., Porter, M. L., & Kimball, A. B. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319851640 · Cited by 62
Reacciones paradójicas de los tratamientos biológicos utilizados en psoriasis: revisión de la literatura
Munera‐Campos, M., Ballescá, F., & Carrascosa, J. M. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2018.04.003 · Cited by 61
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
Martora, F., Scalvenzi, M., Ruggiero, A., Potestio, L., Battista, T., & Megna, M. (2023) · Medicina · doi:10.3390/medicina59040801 · Cited by 60
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study
Kozera, E. K., Flora, A., & Frew, J. W. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.07.047 · Cited by 59
Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review
Abdallah, H. B., Fogh, K., & Bech, R. (2019) · International Wound Journal · doi:10.1111/iwj.13067 · Cited by 57
Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients
Savage, K. T., Santillan, M. R., Flood, K. S., Charrow, A. P., Porter, M. L., & Kimball, A. B. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.10.010 · Cited by 57
Persistent Release of IL-1s from Skin Is Associated with Systemic Cardio-Vascular Disease, Emaciation and Systemic Amyloidosis: The Potential of Anti-IL-1 Therapy for Systemic Inflammatory Diseases
Yamanaka, K., Nakanishi, T., Saito, H., Maruyama, J., Isoda, K., Yokochi, A., Imanaka‐Yoshida, K., Tsuda, K., Kakeda, M., Okamoto, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104479 · Cited by 54
Self-citation
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients
Weber, P., Jafari, S. M. S., Yawalkar, N., & Hunger, R. E. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.02.026 · Cited by 53
Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression
Ortega‐Loayza, A. G., Friedman, M., Reese, A. M., Liu, Y., Greiling, T. M., Cassidy, P. B., Marzano, A. V., Gao, L., Fei, S. S., & Rosenbaum, J. T. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.08.431 · Cited by 53
Interleukin‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum
Navrazhina, K., Frew, J. W., Grand, D., Williams, S. C., Hur, H. B., Gonzalez, J., Garcet, S., & Krueger, J. G. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21060 · Cited by 53
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa
Aarts, P., Dudink, K., Vossen, A. R. J. V., van Straalen, K. R., Ardon, C. B., Prens, E. P., & van der Zee, H. H. (2021) · Drugs · doi:10.1007/s40265-021-01566-2 · Cited by 52
Guselkumab in the treatment of severe hidradenitis suppurativa
Kovács, M., & Podda, M. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15368 · Cited by 50
“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events
Yamanaka, K., & Mizutani, H. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.009 · Cited by 47
Self-citation
Systematic review of immunomodulatory therapies for hidradenitis suppurativa
Lim, S. Y. D., & Oon, H. H. B. (2019) · Biologics · doi:10.2147/btt.s199862 · Cited by 46
Biologic and small-molecule medications in the management of pyoderma gangrenosum
McKenzie, F., Cash, D. R., Gupta, A. S., et al. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1506083 · Cited by 44
T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum
Antiga, E., Maglie, R., Volpi, W., et al. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12989 · Cited by 42
Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor
Nasifoglu, S., Heinrich, B., & Welzel, J. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16468 · Cited by 42
Clinical, microbiological, immunological and imaging characteristics of tunnels and fistulas in hidradenitis suppurativa and Crohn’s disease
Jørgensen, A. R., Thomsen, S. F., Karmisholt, K. E., & Ring, H. C. (2019) · Experimental Dermatology · doi:10.1111/exd.14036 · Cited by 42
Biologics for Hidradenitis Suppurativa: An Update
Włodarek, K., Ponikowska, M., Matusiak, Ł., & Szepietowski, J. C. (2018) · Immunotherapy · doi:10.2217/imt-2018-0090 · Cited by 39
Clinical guidance of pyoderma gangrenosum 2022
Yamamoto, T., Yamasaki, K., Yamanaka, K., et al. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.16845 · Cited by 39
Self-citation
Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum
Ortega‐Loayza, A. G., Nugent, W. H., Lucero, O. M., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15837 · Cited by 38
Tofacitinib for the treatment of refractory pyoderma gangrenosum
Orfaly, V. E., Kovalenko, I., Tolkachjov, S. N., et al. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14683 · Cited by 38
Pyoderma Gangrenosum and Interleukin Inhibitors: A Semi-Systematic Review
Abdallah, H. B., Fogh, K., Vestergaard, C., et al. (2021) · Dermatology · doi:10.1159/000519320 · Cited by 38
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
Kerdel, F., Azevedo, F. A., Don, C. K., Don, F. A., Fabbrocini, G., & Kerdel, F. A. (2019) · PubMed · Cited by 37
Successful treatment of a refractory pyoderma gangrenosum with risankizumab
Burgdorf, B., Schlott, S., Ivanov, I. H., et al. (2020) · International Wound Journal · doi:10.1111/iwj.13359 · Cited by 37
Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi®)
Shanmugam, V. K., McNish, S., Shara, N. M., Hubley, K., Kallakury, B., Dunning, D. M., Attinger, C. E., & Steinberg, J. S. (2013) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2013.07.003 · Cited by 35
Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum
Laird, M. E., Tong, L. X., Sicco, K. I. L., et al. (2017) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.02.019 · Cited by 34
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study
Yamasaki, K., Yamanaka, K., Zhao, Y., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15533 · Cited by 34
Self-citation
Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
Scheinberg, M. A., Machado, L. A. D. P., Castro, L. G. M., et al. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100099 · Cited by 34
Systematic review of immunomodulatory therapies for hidradenitis suppurativa
Lim, S. Y. D., & Oon, H. H. B. (2019) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 33
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study
Yamasaki, K., Yamanaka, K., Zhao, Y., et al. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16337 · Cited by 32
Self-citation
Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum
Baier, C., & Barak, O. G. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.12.005 · Cited by 30
Rapid resolution of pyoderma gangrenosum with brodalumab therapy
Tee, M. W., Avarbock, A. B., Ungar, J. P., et al. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.08.033 · Cited by 27
Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis
Huang, C., Huang, I., Tai, C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061303 · Cited by 27
JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum
Castro, L. G. M. (2023) · International Journal of Dermatology · doi:10.1111/ijd.16676 · Cited by 27
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders
Aarts, P., Vossen, A. R. J. V., van der Zee, H. H., Prens, E. P., & van Straalen, K. R. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.08.113 · Cited by 26
Modified dose of guselkumab for treatment of pyoderma gangrenosum
Reese, A. M., Erickson, K. M., Reed, K. B., et al. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.11.030 · Cited by 26
First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab
Sadik, C. D., Thieme, M., Zillikens, D., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15714 · Cited by 25
Ustekinumab treatment for hidradenitis suppurativa
Takeda, K., Kikuchi, K., Kanazawa, Y., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15122 · Cited by 25
Inflammatory Skin-Derived Cytokines Accelerate Osteoporosis in Mice with Persistent Skin Inflammation
Mizutani, K., Isono, K., Matsushima, Y., Okada, K., Umaoka, A., Iida, S., Habe, K., Hagimori, K., Yamazaki, H., & Yamanaka, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103620 · Cited by 24
Self-citation
Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes
Westerdahl, J. S., Nusbaum, K. B., Chung, C. G., et al. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1937475 · Cited by 24
Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review
Orita, A., Hoshina, D., & Hirosaki, K. (2022) · Clinical and Experimental Dermatology · doi:10.1111/ced.15183 · Cited by 24
Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey
Yamamoto, T. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14658 · Cited by 23
Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials
van der Zee, H. H., Longcore, M., Geng, Z., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16023 · Cited by 22
Janus Kinase Inhibitors Ameliorated Gastrointestinal Amyloidosis and Hypoalbuminemia in Persistent Dermatitis Mouse Model
Nakanishi, T., Mizutani, K., Iida, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010028 · Cited by 21
An update on adalimumab for pyoderma gangrenosum
Yamamoto, T. (2021) · Drugs of today · doi:10.1358/dot.2021.57.9.3293619 · Cited by 17
Different molecular pathways are disrupted in Pyoderma gangrenosum patients and are associated with the severity of the disease
de Moura, R. R., Brandão, L. A. C., Moltrasio, C., Agrelli, A., Tricarico, P. M., Maronese, C. A., Crovella, S., & Marzano, A. V. (2023) · Scientific Reports · doi:10.1038/s41598-023-31914-z · Cited by 17
The Stenosis of Cerebral Arteries and Impaired Brain Glucose Uptake by Long-Lasting Inflammatory Cytokine Release from Dermatitis Is Rescued by Anti-IL-1 Therapy
Kato, S., Matsushima, Y., Mizutani, K., Kawakita, F., Fujimoto, M., Okada, K., Kondo, M., Habe, K., Suzuki, H., Mizutani, H., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.04.016 · Cited by 15
Self-citation
Dual‐targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease
Vernero, M., Ribaldone, D. G., Cariti, C., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15283 · Cited by 15
IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease
Iida, S., Nakanishi, T., Momose, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105726 · Cited by 15
Skin Inflammation and Testicular Function: Dermatitis Causes Male Infertility via Skin-Derived Cytokines
Umaoka, A., Takeuchi, H., Mizutani, K., Seo, N., Matsushima, Y., Habe, K., Hagimori, K., Yamaguchi, Y., Ikeda, T., & Yamanaka, K. (2020) · Biomedicines · doi:10.3390/biomedicines8090293 · Cited by 13
Self-citation
Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study
Deckers, I. E., van der Zee, H. H., Balak, D., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13346 · Cited by 12
A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs
Holcomb, Z. E., Porter, M. L., & Kimball, A. B. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1924147 · Cited by 11
Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
Nishimura, M., Mizutani, K., Yokota, N., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236924 · Cited by 10
Treatment of pyoderma gangrenosum with apremilast monotherapy
Bordeaux, Z. A., Kwatra, S. G., & West, C. E. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2022.10.001 · Cited by 9
Arteriosclerosis Derived from Cutaneous Inflammation Is Ameliorated by the Deletion of IL-17A and IL-17F
Nakanishi, T., Iida, S., Maruyama, J., Urushima, H., Ichishi, M., Matsushima, Y., Mizutani, K., Nakayama, Y., Sugioka, K., Nishimura, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065434 · Cited by 9
Self-citation
Whether to maintain or strengthen the treatment for pyoderma gangrenosum ulcerative type may depend on the response after two to four‐week treatment intervention: The outcome of three cases with details clinical course
Nakayama, Y., Akeda, T., Iida, S., et al. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4690 · Cited by 7
Inflammatory Skin Disease Causes Anxiety Symptoms Leading to an Irreversible Course
Iida, S., Shoji, H., Kawakita, F., Nakanishi, T., Matsushima, Y., Kondo, M., Habe, K., Suzuki, H., Miyakawa, T., & Yamanaka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065942 · Cited by 6
Self-citation
Off-label use of guselkumab for pyoderma gangrenosum
Piñeiro, L. V., Martínez, M. L., & Pin, A. I. C. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.04.024 · Cited by 3
Tratamiento del pioderma gangrenoso con guselkumab en condiciones diferentes a las autorizadas en la ficha técnica
Piñeiro, L. V., Martínez, M. L., & Pin, A. I. C. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.04.029 · Cited by 3
Hidradenitis Suppurativa
Preda‐Naumescu, A., Sowell, J., Ahmed, H. N., et al. (2022) · Clinical Dermatology Review · doi:10.4103/cdr.cdr_53_21 · Cited by 1

The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1
“Although several aspects remain unclear, immune mechanisms are central to vitiligo pathogenesis [46].”

See all 19

Authors: Yamanaka, K.
Affiliations: Mie University (JP)
Corresponding author: Yamanaka, Keiichi
ORCID: Yamanaka, Keiichi
Venue: The Journal of Dermatology
Publisher: Wiley
Published: 2023-11-27
Volume: 51
Issue: 2
Pages: 172-179
ISSN: 0385-2407 (ISSN-L)
1346-8138
DOI: 10.1111/1346-8138.17031
PMC: PMC11483966
OpenAlex: W4389069982
Cited by: 19
References: 93
Citations by year: 2026: 6 · 2025: 8 · 2024: 5
FWCI: 0.74
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: The Journal of Dermatology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Dermatology › Autoimmune and Inflammatory Disorders
Health Sciences › Medicine › Dermatology › Hidradenitis Suppurativa and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords: pyoderma gangrenosum, hidradenitis suppurativa, cytokine therapy, TNF-α, interleukin-1, IL-17, IL-23, interleukin-8, JAK inhibitors, cyclosporine, immunosuppressants, autoinflammatory skin disease
MeSH terms: Dermatitis, Humans, Skin, Cytokines, Hidradenitis Suppurativa, Pyoderma Gangrenosum

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks

Data sources